Brookline Capital Management Weighs in on CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Stock analysts at Brookline Capital Management dropped their Q1 2025 EPS estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, March 26th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.30) for the quarter, down from their prior estimate of ($0.29). Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.43) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($2.07) EPS.

A number of other research analysts have also commented on the company. Royal Bank of Canada lowered their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $1.96 on Monday. Perspective Therapeutics has a one year low of $1.90 and a one year high of $19.05. The company’s fifty day moving average price is $2.88 and its two-hundred day moving average price is $6.10.

Insiders Place Their Bets

In other news, Director Robert F. Williamson III acquired 22,192 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The stock was bought at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the transaction, the director now owns 70,837 shares of the company’s stock, valued at $160,799.99. The trade was a 45.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Juan Graham acquired 33,333 shares of the stock in a transaction dated Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now owns 35,354 shares of the company’s stock, valued at $79,546.50. This trade represents a 1,649.33 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 115,696 shares of company stock worth $256,344 in the last ninety days. Insiders own 3.52% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CATX. FMR LLC increased its stake in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the period. Janus Henderson Group PLC boosted its holdings in Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of Perspective Therapeutics by 4.3% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares during the period. Octagon Capital Advisors LP raised its holdings in shares of Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after buying an additional 882,528 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after buying an additional 1,192,812 shares during the period. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.